Strategic Partners A/S

Strategic Partners A/S P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Strategic Partners A/S (STRAP.CO) as of Oct 15, 2026 is -10.97. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -6.97 — a change of 57.35% (lower).

P/FCF

-10.97

YoY

57.35%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Strategic Partners A/S is 2025 -10.97 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Strategic Partners A/S was 2024 -6.97 . It decreases by 57.35% lower compared to the previous year.

The Strategic Partners A/S P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-0.10 DKK
Jan 1, 2019
-0.07 DKK
Jan 1, 2020
-0.04 DKK
Jan 1, 2021
-0.04 DKK
Jan 1, 2022
-0.20 DKK
Jan 1, 2023
-1.17 DKK
Jan 1, 2024
-6.97 DKK
Jan 1, 2025
-10.97 DKK
The Strategic Partners A/S P/FCF history
YEARP/FCFYoY
-10.97+57.35%
-6.97+495.69%
-1.17+489.11%
-0.20+411.73%
-0.04-9.84%
-0.04-39.34%
-0.07-28.17%
-0.10-59.13%
-0.24-43.29%
-0.43-14.66%
-0.50-21.13%
-0.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Strategic Partners A/S is -10.97 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Strategic Partners A/S changed from -6.97 to -10.97, representing a 57.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Strategic Partners A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Strategic Partners A/S

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Strategic Partners A/S